Navigation Links
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Date:6/26/2008

ve crisis.

Eli Lilly and Company and Boehringer Ingelheim

In November 2002, Eli Lilly and Company and Boehringer Ingelheim signed a long-term agreement to jointly develop and commercialize duloxetine hydrochloride. This partnership covers neuroscience indications in most countries outside of the United States and Japan, with few exceptions.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.co.uk.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.co.uk.

Duloxetine for major depressive episodes is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Greece, Italy and Spain. In Greece, Italy and Spain Lilly markets the product as Cymbalta and Boehring
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
3. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
4. XTENT Announces European Regulatory Update
5. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
6. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
7. European Unions CHMP Issues Positive Opinion on Sugammadex
8. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
9. PRoFESS(R) Results Announced at XVII European Stroke Conference
10. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
11. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
(Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 The ... vaginal mesh lawsuits filed against C.R. Bard, Inc. ... Court, Southern District of West Virginia. According to ... Conference was convened that day, after certain defendants ... Form Complaint. The Order directed that any Preliminary ...
(Date:4/25/2015)... BWI (PRWEB) April 25, 2015 An ... celebrated three months of successfully welcoming visitors to the ... 2015. , As part of a major construction ... airport was completely redesigned to speed up arrivals. ... process of getting out of the airport and onto ...
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse ... case with the Miami Dolphins and Richie Incognito, or off the ... Rice domestic abuse case. In a recent episode of SCI ... implications of locker room culture on teams. He examines what worked ... do to improve the locker room as a work place. ...
(Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
Cached Medicine News:
Spyglass angiography catheters, combined with St. Jude Medical hemostasis introducers and GuideRight guidewires, offer a safe and effective diagnostic angiography system....
These are coronary angiographic catheters used for selective coronary bypass angiography. The catheters curve configuration is ideally suited to select the internal mammary artery....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: